Seelos Therapeutics Inc (SEEL)

[RVL]

DG,
I agree with you recent posts regarding PR & Phase 4 testing.
Three additional points:
1. I would postulate that vitaros in Canada will be an Abbvie product. Please take a look at announcement regarding Abbvie & Abbott split.

Http://www.sec.gov/Archives/edgar/data/1551152/000104746912006434/a2209760zex-99_1.htm

2. If there are Phase 4 studies in Canada, they are being conducted by Abbvie not Apricus. Therefore, PR is controlled by Abbvie & Abbvie has a lot going on right now, with positioning pipeline. When they do start discussing Vitaros in Canada, I think it is a small opportunity for them.

3. I am hoping / speculating that Abbvie is more interested in Femprox & the huge untapped opportunity for women. Abbott/Abbvie has proven that they believe in Nextact with Apricus/Canada deal and there is an array of potential existing drug products that Abbott/Abbvie have that could be used in Nextact topical dosage form.
Therefore, I believe the delay with Vitaros in Canada and the firing of Damaj is secondary to Abbvie separation from Abbott & Damaj' reluctance to sell Apricus. My thinking is the run up is secondary to the pending acquisition of Apricus by Abbvie NOT the numerous opportunities that we know are projected in 2013.

RVL